Evolution of melanoma cross-resistance to CD8(+) T cells and MAPK inhibition in the course of BRAFi treatment

The profound but frequently transient clinical responses to BRAF(V600) inhibitor (BRAFi) treatment in melanoma emphasize the need for combinatorial therapies. Multiple clinical trials combining BRAFi and immunotherapy are under way to further enhance therapeutic responses. However, to which extent B...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncoimmunology
Autori principali: Pieper, Natalia, Zaremba, Anne, Leonardelli, Sonia, Harbers, Franziska Noelle, Schwamborn, Marion, Lübcke, Silke, Schrörs, Barbara, Baingo, Jolanthe, Schramm, Alexander, Haferkamp, Sebastian, Seifert, Ulrike, Sucker, Antje, Lennerz, Volker, Wölfel, Thomas, Schadendorf, Dirk, Schilling, Bastian, Paschen, Annette, Zhao, Fang
Natura: Artigo
Lingua:Inglês
Pubblicazione: Taylor & Francis 2018
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6136878/
https://ncbi.nlm.nih.gov/pubmed/30221038
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2018.1450127
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi